alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › eligibility

eligibility

3 studies tagged eligibility, dated 2024-07-06 to 2026-11-09. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Rapid Apolipoprotein E ε4 Proteotyping for Alzheimer's Disease Anti-Amyloid Therapy Eligibility and Risk Assessment 2026-11-09
  2. Eligibility for anti-amyloid treatment in a multiethnic community-based study 2026-04-01
  3. Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer's disease 2024-07-06

Studies

3 studies carry this tag.

Date range

2024 to 2026

Top journals

  • Alzheimer's & dementia (Amsterdam, Netherlands) 1
  • Alzheimer's research & therapy 1
  • The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Rapid Apolipoprotein E ε4 Proteotyping for Alzheimer's Disease Anti-Amyloid Therapy Eligibility and Risk Assessment

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2026-11-09 Treatments

    Proteotyping reliably rules out E4/E4 homozygosity (100% NPV), enabling rapid eligibility screening for anti-amyloid therapies.

  2. Eligibility for anti-amyloid treatment in a multiethnic community-based study

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2026-04-01 Treatments

    Few individuals in this community-based, multiethnic cohort met eligibility for anti-amyloid therapy, highlighting limited real-world applicability of current AURs.

  3. Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 74 out of 100. Alzheimer's research & therapy 2024-07-06 Biomarkers

    Potential DMT candidates at Butler MAP (n = 50), primarily diagnosed with mild cognitive impairment (n = 29 [58%]) or mild dementia (21 [42%]), were predominantly Aβ-positive (38 [76%]), and half (25 [50%]) were subsequently treated with aducanumab.

All topic tags with their study counts